Elleste Solo MX80 micrograms Transdermal Patch
Last Updated on eMC 13-May-2016 View document | Meda Pharmaceuticals Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 13-May-2016 and displayed until Current
Reasons for adding or updating:
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Date of revision of text on the SPC: 04-Mar-2016
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
IAIN Variation -C.I.z - Change(s) in the Summary of product Characteristics, Labelling orPackage Leaflet intended to implement the outcome of a PRAC signal recommendation:implementation of wording agreed by the competent authority that do not requireany further assessmentUpdated on 17-Apr-2015 and displayed until 13-May-2016
Reasons for adding or updating:
- Improved presentation of SPC
Date of revision of text on the SPC: 22-Jan-2014
Legal Category:POM
Black Triangle (CHM): NO
Updated on 09-Jul-2014 and displayed until 17-Apr-2015
Reasons for adding or updating:
- Change to section 6.1 - List of excipients
Date of revision of text on the SPC: 11-Nov-2013
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Type IB variation to change the excipients to section 6.1Updated on 24-Apr-2012 and displayed until 09-Jul-2014
Reasons for adding or updating:
- Change to section 4.1 - Therapeutic indications
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for Use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable Effects
- Change to section 5.1 - Pharmacodynamic Properties
- Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC: 15-Mar-2012
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
To update sections 4.1, 4.3, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SPC in line with the core HRT SPC and BNF
Updated on 19-Aug-2009 and displayed until 24-Apr-2012
Reasons for adding or updating:
- Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC: 01-Aug-2009
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Change to Section 7. Marketing Authorisation Holder detailsUpdated on 27-Mar-2009 and displayed until 19-Aug-2009
Reasons for adding or updating:
- Change to section 9 - Date of first Authorisation/renewal of the Authorisation
- Change to section 10 date of revision of the text
Date of revision of text on the SPC: 01-Mar-2009
Legal Category:POM
Black Triangle (CHM): NO
Free-text change information supplied by the pharmaceutical company:
Section 9. Date of First AuthorisationSection 10. Date of Revision of Text
Updated on 05-Sep-2008 and displayed until 27-Mar-2009
Reasons for adding or updating:
- New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Legal Category:POM
Black Triangle (CHM): NO
Meda Pharmaceuticals
Sky Way House, Parsonage Road, Takeley, Bishop's Stortford, CM22 6PU
0845 460 0002
+44 (0)1748 828 810
0845 460 0000
+44 (0)1748 828 810
+44 (0)1748 828 801
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue